Key result
Genetic evidence links cGMP signaling to chronic cardiovascular disease risk including CAD and MI.
Why the study?
Genetic studies have suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, prompting a review linking genetic findings and mechanisms to disease phenotypes.
This review highlights the role of cGMP signaling in cardiovascular diseases, linking genetic findings to phenotypic outcomes such as coronary artery disease and myocardial infarction.
Genetic associations implicate cGMP signaling in CAD and MI risk; hypothesis-generating and requires prospective validation before clinical consideration.
Cyclic guanosine 3',5'-monophosphate (cGMP) is the key second messenger molecule in nitric oxide signaling. Its rapid generation and fate, but also its role in mediating acute cellular functions has been extensively studied. In the past years, genetic studies suggested an important role for cGMP in affecting the risk of chronic cardiovascular diseases, for example, coronary artery disease and myocardial infarction. Here, we review the role of cGMP in atherosclerosis and other cardiovascular diseases and discuss recent genetic findings and identified mechanisms. Finally, we highlight open questions and promising research topics.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2020) conducted a review in Cardiovascular diseases. cGMP signaling was evaluated. Recent genetic studies suggest an important role for cGMP signaling in affecting the risk of chronic cardiovascular diseases, including coronary artery disease and myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: